Melanoma pp 591-604 | Cite as

Management of Non-melanoma Skin Cancers: Basal Cell Carcinoma, Squamous Cell Carcinoma

  • Sheila Jalalat
  • Corin Agoris
  • Neil Alan Fenske
  • Basil CherpelisEmail author


With non-melanoma skin cancer on the rise, representing the most common malignancy, recognition, as well as an appropriate treatment approach is essential for management of these potentially life-threatening lesions. The growing incidence of cutaneous malignancies has heralded the need for multiple treatment options based on the aggressiveness of the lesion, as well as patient-specific factors determining risk. This chapter will start by discussing the incidence and trends of non-melanoma skin cancer. Next, risk factors for the various types of non-melanoma skin cancers, including both genetic and environmental exposures, will be highlighted. Furthermore, education and preventative factors such as sun safety and nonmelanoma skin cancer prophylaxis measures will also be discussed. The main subtypes of cutaneous pre-cancerous and cancerous lesions including actinic keratosis, squamous cell carcinoma in situ, squamous cell carcinoma, and basal cell carcinoma will be presented in detail. Although surgical intervention remains the mainstay treatment for the management of skin cancers, various other treatment modalities and their indications for use will be outlined in this chapter.


Non-melanoma Skin cancer Surgery Medical Cutaneous Management Treatment 


  1. 1.
    Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006;184(1):6–10.PubMedGoogle Scholar
  2. 2.
    Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol. 2000;42(1 Pt 2):18–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Zanetti R, Rosso S, Martinez C, Nieto A, Miranda A, Mercier M, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;94(5):743–51.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Almahroos M, Kurban AK. Ultraviolet carcinogenesis in nonmelanoma skin cancer. Part I: incidence rates in relation to geographic locations and in migrant populations. Skinmed. 2004;3(1):29–35. quiz 35–6PubMedCrossRefGoogle Scholar
  5. 5.
    Hemminki K, Zhang H, Czene K. Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol. 2003;139(7):885–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Karagas MR, Stannard VA, Mott LA, Slattery MJ, Spencer SK, Weinstock MA. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst. 2002;94(3):224–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Lichter MD, Karagas MR, Mott LA, Spencer SK, Stukel TA, Greenberg ER. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Ott C, Huber S. The clinical significance of cosmic radiation in aviation. Praxis. 2006;95(4):99–106.PubMedCrossRefGoogle Scholar
  9. 9.
    Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1–17. quiz 18–20PubMedCrossRefGoogle Scholar
  10. 10.
    Comeau S, Jensen L, Cockfield SM, Sapijaszko M, Gourishankar S. Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience. Transplantation. 2008;86(4):535–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Karagas MR, Cushing GL, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer. 2001;85(5):683–6.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol. 1994;130(8):1018–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Summers CG. Albinism: classification, clinical characteristics, and recent findings. Optom Vis Sci. 2009;86(6):659–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res. 1997;57(19):4214–6.PubMedGoogle Scholar
  16. 16.
    Fine J-D, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009;61(3):387–402. quiz 403–4PubMedCrossRefGoogle Scholar
  17. 17.
    Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69(3):299–308.PubMedCrossRefGoogle Scholar
  18. 18.
    Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine. 1991;70(4):269–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol. 2012;22(3):299–309.PubMedGoogle Scholar
  20. 20.
    Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017;76(4):632–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Bolognia J. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012.Google Scholar
  22. 22. Skin cancer (Non-Melanoma): risk factors and prevention; 2016.Google Scholar
  23. 23.
    Yuspa SH. Cutaneous chemical carcinogenesis. J Am Acad Dermatol. 1986;15(5 Pt 1):1031–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Simeonova PP, LUSTER MI. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol. Begell House. 2000;19(3):281–6.PubMedGoogle Scholar
  25. 25.
    Australian Cancer Network: CCA. Basal cell carcinoma, squamous cell carcinoma (and related lesions) – a guide to clinical management in Australia. Cancer Council Australia/Australian Cancer Network Sydney; 2008.Google Scholar
  26. 26.
    Freiman A, Bird G, Metelitsa AI, Barankin B, Lauzon GJ. Cutaneous effects of smoking. J Cutan Med Surg. 2004;8(6):415–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Iannacone MR, Wang W, Stockwell HG, O’Rourke K, Giuliano AR, Sondak VK, et al. Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study. BMC Cancer. 2012;12:417.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(Suppl 3):78–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54(6):933–46. quiz 947–50PubMedCrossRefGoogle Scholar
  30. 30.
    Rudnick EW, Thareja S, Cherpelis B. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. Int J Dermatol. 2016;55(3):249–58. quiz 256, 258PubMedCrossRefGoogle Scholar
  31. 31.
    Fu T, Aasi SZ, Hollmig ST. Management of high-risk squamous cell carcinoma of the skin. Curr Treat Options in Oncol. 2016;17(7):34.CrossRefGoogle Scholar
  32. 32.
    Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of Nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618–26.PubMedCrossRefGoogle Scholar
  33. 33.
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical Tretinoin chemoprevention trial. Cancer. 2009;115(11):2523–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Gupta AK, Cooper EA, Feldman SR Jr, Fleischer AB Jr. A survey of office visits for actinic keratosis as reported by NAMCS, 1990–1999. National Ambulatory Medical Care Survey. Cutis. 2002;70(2 Suppl):8–13.PubMedGoogle Scholar
  36. 36.
    Yu RC, Pryce DW, Macfarlane AW, Stewart TW. A histopathological study of 643 cutaneous horns. Br J Dermatol. 1991;124(5):449–52.PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartz RA. Keratoacanthoma. J Am Acad Dermatol. 1994;30(1):1–19. quiz 20–2PubMedCrossRefGoogle Scholar
  38. 38.
    Norgauer J, Rohwedder A, Schaller J. Human papillomavirus and Grzybowski’s generalized eruptive keratoacanthoma. J Am Acad Dermatol. 2003;49(4):771–2.PubMedCrossRefGoogle Scholar
  39. 39.
    NCCN. National Comprehensive Cancer Network Guidelines; 2017.Google Scholar
  40. 40.
    Network NCC. Basal cell carcinoma (version1.2017).Google Scholar
  41. 41.
    August PJ. Cryotherapy of nonmelanoma skin cancer. Clin Dermatol. 1995;13(6):589–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Bahner JD, Bordeaux JS. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013;31(6):792–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30(2 Pt 2):297–300.PubMedGoogle Scholar
  44. 44.
    Graham GF, Clark LC. Statistical analysis in cryosurgery of skin cancer. Clin Dermatol. 1990;8(1):101–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Kokoszka A, Scheinfeld N. Evidence-based review of the use of cryosurgery in treatment of basal cell carcinoma. Dermatol Surg. 2003;29(6):566–71.PubMedGoogle Scholar
  46. 46.
    Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159(1):35–48.PubMedCrossRefGoogle Scholar
  47. 47.
    Divine J, Stefaniwksy L, Reddy R, Padilla P, Hagele T, Patel NS, et al. A comprehensive guide to the surgical management of nonmelanoma skin cancer. Curr Probl Cancer. 2015;39(4):216–25.PubMedCrossRefGoogle Scholar
  48. 48.
    Graham G. Electrodesiccation and curettage. In: Macfarlane D, editor. Skin cancer management. 1st ed. New York: Springer; 1988. p. 79–82.Google Scholar
  49. 49.
    Jackson R, Laughlin S. Electrodesiccation and curettage. In: Schwartz RA, editor. Skin cancer. 1st ed. New York: Springer. p. 292–5.CrossRefGoogle Scholar
  50. 50.
    NCCN. Basal cell carcinoma (version 1.2017); 2017.Google Scholar
  51. 51.
    Jackson R. The treatment of skin cancer by electrodesiccation and curettage. J Surg Oncol. 1983;22(2):100.PubMedCrossRefGoogle Scholar
  52. 52.
    Roenigk RK, Roenigk HH. Current surgical management of skin cancer in dermatology. J Dermatol Surg Oncol. 1990;16(2):136–51.PubMedCrossRefGoogle Scholar
  53. 53.
    Honeycutt WM, Jansen GT. Treatment of squamous cell carcinoma of the skin. Arch Dermatol. 1973;108(5):670–2.PubMedCrossRefGoogle Scholar
  54. 54.
    Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Plast Surg. 2003;56(2):85–91.PubMedCrossRefGoogle Scholar
  55. 55.
    Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 1: overview. J Dermatol Surg Oncol. 1991;17(9):713–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123(3):340–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Silapunt S, Jih MH. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol. 2005;53(3):464–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev. 2014;12:CD007041.Google Scholar
  61. 61.
    Bogdanov-Berezovsky A, Cohen AD, Glesinger R, Cagnano E, Rosenberg L. Risk factors for incomplete excision of squamous cell carcinomas. J Dermatolog Treat. 2005;16(5–6):341–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4(8):462–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.PubMedGoogle Scholar
  64. 64.
    Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50(5):714–21.PubMedCrossRefGoogle Scholar
  65. 65.
    Szeimies R-MM, Gerritsen M-JPJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547–55.PubMedCrossRefGoogle Scholar
  66. 66.
    Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141(4):467–73.PubMedCrossRefGoogle Scholar
  67. 67.
    Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156(Suppl 3):25–33.PubMedCrossRefGoogle Scholar
  68. 68.
    Metterle L, Russell JS, Patel NS. An overview of the medical management of nonmelanoma skin cancer. Curr Probl Cancer. 2015;39(4):226–36.PubMedCrossRefGoogle Scholar
  69. 69.
    Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709–13.PubMedCrossRefGoogle Scholar
  70. 70.
    Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44(1):40–3.PubMedCrossRefGoogle Scholar
  71. 71.
    Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–70.PubMedCrossRefGoogle Scholar
  72. 72.
    Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934–43.PubMedCrossRefGoogle Scholar
  73. 73.
    Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Arits AHH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–54.PubMedCrossRefGoogle Scholar
  75. 75.
    Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-Fluorouracil. J Cutan Med Surg. 2003;7(2):101–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165–71.PubMedCrossRefGoogle Scholar
  77. 77.
    Schiessl C, Wolber C, Tauber M, Offner F, Strohal R. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol. 2007;6(5):507–13.PubMedGoogle Scholar
  78. 78.
    Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% Imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99–105.PubMedCrossRefGoogle Scholar
  80. 80.
    Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatol Surg. 2013;39(9):1306–16.PubMedCrossRefGoogle Scholar
  81. 81.
    Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63(4):689–702.PubMedCrossRefGoogle Scholar
  82. 82.
    Kraus S, Miller BH, Swinehart JM, Shavin JS, Georgouras KE, Jenner DA, et al. Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1998;38(3):438–42.PubMedCrossRefGoogle Scholar
  83. 83.
    Jarkowski A, Hare R, Loud P, Skitzki JJ, Kane JM, May KS, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature. Am J Clin Oncol. 2016;39(6):545–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22(1):32–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Guthrie TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Santana AL, Felsen D, Carucci JA. Interleukin-22 and cyclosporine in aggressive cutaneous squamous cell carcinoma. Dermatol Clin. 2017;35(1):73–84.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28.PubMedCrossRefGoogle Scholar
  90. 90.
    Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther. 2015;15(6):787–801.PubMedCrossRefGoogle Scholar
  91. 91.
    Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol. 1998;39(5 Pt 1):698–703.PubMedCrossRefGoogle Scholar
  92. 92.
    Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg. 2010;36(5):652–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg. 2004;30(2 Pt 2):264–71.PubMedGoogle Scholar
  94. 94.
    Rhodes LE, de Rie M, Enström Y, Groves R, Morken T, Goulden V, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23.PubMedCrossRefGoogle Scholar
  95. 95.
    Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg. 2002;28(3):268–73.PubMedGoogle Scholar
  96. 96.
    Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Jambusaria-Pahlajani A, Hess SD, Katz KA, Berg D, Schmults CD. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol. 2010;146(11):1225–31.PubMedCrossRefGoogle Scholar
  98. 98.
    Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33(8):885–99.PubMedGoogle Scholar
  99. 99.
    Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(11):1214–40.PubMedCrossRefGoogle Scholar
  100. 100.
    Kauvar AN, Cronin T, Roenigk R, Hruza G, Bennett R. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(5):550–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sheila Jalalat
    • 1
  • Corin Agoris
    • 2
  • Neil Alan Fenske
    • 1
  • Basil Cherpelis
    • 1
    Email author
  1. 1.Department of Dermatology and Cutaneous SurgeryMorsani College of Medicine, University of South FloridaTampaUSA
  2. 2.Morsani College of MedicineUniversity of South FloridaTampaUSA

Personalised recommendations